Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 4/20 | 0.44 |
| ▸ | GLB1 | P16278 | 1/20 | 0.41 |
| ▸ | GUSB | P08236 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | HRH2 | P25021 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921265 | 0.84 | HRH3 (0.49) | HTR1AHRH3HRH2HRH1 | |
| SCHEMBL12717290 | 0.84 | HRH3 (0.49) | HTR1AHRH3HRH2HRH1 | |
| SCHEMBL13552419 | 0.84 | HRH3 (0.49) | HTR1AHRH3HRH2HRH1 | |
| SCHEMBL12717292 | 0.81 | HTR1A (0.58) | HTR1AHRH3HRH2HRH1 | |
| SCHEMBL20698407 | 0.81 | HTR1A (0.58) | HTR1AHRH3HRH2HRH1 | |
| SCHEMBL14419811 | 0.81 | HTR1A (0.58) | HTR1AHRH3HRH2HRH1 | |
| SCHEMBL12717293 | 0.79 | HRH3 (0.47) | GBA1SIGMAR1HRH3HRH2HRH1 | |
| SCHEMBL21000316 | 0.79 | GLB1 (0.42) | GBA1GLB1GUSBHTR1ASIGMAR1 | |
| SCHEMBL23023305 | 0.78 | GBA1 (0.37) | GBA1GLB1GUSBSIGMAR1HRH3 | |
| SCHEMBL19174517 | 0.78 | EHMT2 (0.38) | GBA1GLB1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023194458-A1 | N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER | WMT AG (DE) | 2023-10-12 | — | — | WO | disclosed |
| US-11708326-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3664793-B1 | MACROCYCLIC IMMUNOMODULATORS | CHEMOCENTRYX INC (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3658522-B1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210236476-A1 | METHODS OF TREATING CANCER WITH SMALL MOLECULE PD-L1 INHIBITORS | CHEMOCENTRYX, INC. | 2021-08-05 | — | — | US | disclosed |
| WO-2021129820-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUND | 微境生物医药科技(上海)有限公司 | 2021-07-01 | — | — | WO | disclosed |
| WO-2020047035-A1 | METHODS OF TREATING CANCER WITH SMALL MOLECULE PD-L1 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2019032547-A1 | MACROCYCLIC IMMUNOMODULATORS | CHEMOCENTRYX, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019023575-A1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708326-B2 | Immunomodulator compounds | IL2, FCGRT, IFNG | GBA1 1845/4885GLB1 923/4885GUSB 958/4885 |
| US-20210236476-A1 | METHODS OF TREATING CANCER WITH SMALL MOLECULE PD-L1 INHIBITORS | CD4, CD274, PDCD1 | GBA1 4526/4885GLB1 2706/4885GUSB 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.